Your browser is no longer supported. Please, upgrade your browser.
CTMX CytomX Therapeutics, Inc. monthly Stock Chart
CTMX [NASD]
CytomX Therapeutics, Inc.
Index- P/E- EPS (ttm)-1.63 Insider Own21.10% Shs Outstand36.52M Perf Week17.19%
Market Cap649.69M Forward P/E- EPS next Y-2.18 Insider Trans-7.78% Shs Float34.08M Perf Month52.57%
Income-58.90M PEG- EPS next Q-0.36 Inst Own77.00% Short Float1.39% Perf Quarter54.56%
Sales15.00M P/S43.31 EPS this Y66.80% Inst Trans-4.24% Short Ratio2.18 Perf Half Y6.78%
Book/sh2.15 P/B8.27 EPS next Y0.90% ROA-29.80% Target Price20.33 Perf Year39.53%
Cash/sh4.98 P/C3.57 EPS next 5Y14.30% ROE-61.70% 52W Range9.10 - 20.02 Perf YTD61.87%
Dividend- P/FCF- EPS past 5Y- ROI-75.90% 52W High-11.14% Beta-
Dividend %- Quick Ratio5.30 Sales past 5Y- Gross Margin- 52W Low95.49% ATR1.31
Employees78 Current Ratio5.30 Sales Q/Q215.00% Oper. Margin- RSI (14)66.25 Volatility10.24% 8.57%
OptionableNo Debt/Eq0.00 EPS Q/Q1.20% Profit Margin- Rel Volume1.40 Prev Close17.42
ShortableYes LT Debt/Eq0.00 EarningsMar 02 AMC Payout- Avg Volume216.77K Price17.79
Recom1.80 SMA2019.82% SMA5037.99% SMA20047.27% Volume303,598 Change2.12%
Mar-02-17Initiated Instinet Buy $21
Jan-03-17Downgrade Oppenheimer Outperform → Perform
Nov-02-15Initiated Oppenheimer Outperform $17
Nov-02-15Initiated Jefferies Buy $19
Nov-02-15Initiated BofA/Merrill Buy
Mar-24-17 07:47AM  Pharma Stock Roundup: Is Sanofi Buying Flexion? Pfizer, Merck KGaA Drug Approved
Mar-22-17 08:33AM  Biotech Stock Roundup: Amgen Down on Repatha Data, Nektar Surges on Pain Results
Mar-21-17 11:26AM  Bristol-Myers Squibb and CytomX Therapeutics Extend Deal
09:30AM  Stocks of Nektar Therapeutics and CytomX Therapeutics Rise on FDA Trial News Accesswire
Mar-20-17 04:10PM  Bristol-Myers Partner Hits 18-Month High On Immuno-Oncology Deal +24.44%
02:26PM  Heres Why Wells Fargo, eBay, CytomX Therapeutics, Dominion Diamond, and More Are Trending at Insider Monkey
12:52PM  Bristol-Myers, CytomX Extend Cancer Drug Pact at Investopedia
11:56AM  CytomX Therapeutics, Inc. :CTMX-US: Earnings Analysis: Q4, 2016 By the Numbers : March 20, 2017
11:25AM  Biotechs Remain the Best Place For Stock Picking
11:10AM  A small drug company that's trying to make cancer treatments safer just received a $3.8 billion endorsement
10:55AM  Mondays Top Biopharma Movers
09:38AM  Stocks Edge Lower At The Open; Sprouts Up Again On Merger Talk
09:35AM  Biotech Premarket Movers: CytomX, Aevi, Esperion
09:21AM  CytomX Soars on Bristol-Myers Partnership
07:18AM  CytomX's stock rockets after expanding Bristol-Myers collaboration at MarketWatch
07:02AM  CYTOMX THERAPEUTICS, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Regulation FD Disclosure, F
Mar-19-17 07:00PM  CytomX Therapeutics Announces Teleconference and Webcast to Provide Corporate Update GlobeNewswire
Mar-14-17 02:28PM  CytomX Therapeutics, Inc. :CTMX-US: Earnings Analysis: 2016 By the Numbers : March 14, 2017
Mar-08-17 01:04PM  CYTOMX THERAPEUTICS, INC. Financials
Mar-02-17 04:39PM  CytomX Therapeutics reports 4Q loss +9.10%
04:21PM  CYTOMX THERAPEUTICS, INC. Files SEC form 10-K, Annual Report
04:05PM  CytomX Announces Full-Year 2016 Financial Results GlobeNewswire
08:44AM  Coverage initiated on CytomX Therapeutics by Instinet
07:07AM  Q4 2016 CytomX Therapeutics Inc Earnings Release - After Market Close
Mar-01-17 08:00AM  CytomX Therapeutics to Announce Full-Year 2016 Financial Results GlobeNewswire +6.32%
Feb-21-17 04:05PM  CytomX Therapeutics to Present at Upcoming Investor Conferences GlobeNewswire
Feb-14-17 08:29AM  CytomX Therapeutics, Inc. breached its 50 day moving average in a Bullish Manner : CTMX-US : February 14, 2017
Feb-02-17 04:05PM  CytomX to Present at Upcoming Investor Conferences GlobeNewswire
08:00AM  CytomX Announces the First Patient Treated in Phase 1/2 PROCLAIM-072 Trial GlobeNewswire
Jan-31-17 09:27AM  CytomX Therapeutics, Inc. breached its 50 day moving average in a Bearish Manner : CTMX-US : January 31, 2017
Jan-17-17 11:29AM  ETFs with exposure to CytomX Therapeutics, Inc. : January 17, 2017
Jan-13-17 07:22AM  CytomX Therapeutics, Inc. breached its 50 day moving average in a Bullish Manner : CTMX-US : January 13, 2017
Jan-10-17 04:58PM  CYTOMX THERAPEUTICS, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Regulation FD Disclosure
Jan-09-17 06:55PM  UPDATE: CytomX Announces Time Change for its Presentation at the 35th Annual J.P. Morgan Healthcare Conference GlobeNewswire
08:00AM  CytomX to Present at the 35th Annual J.P. Morgan Healthcare Conference GlobeNewswire
Jan-03-17 09:25AM  Athene, Barracuda, Energizer, Michael Kors, Tableau Software and Many More in Key Analyst Calls for Tuesday
Dec-27-16 10:32AM  CytomX Therapeutics, Inc. Value Analysis (NASDAQ:CTMX) : December 27, 2016 -8.75%
Dec-26-16 07:29AM  CytomX Therapeutics, Inc. breached its 50 day moving average in a Bullish Manner : CTMX-US : December 26, 2016
Dec-14-16 08:03AM  CYTOMX THERAPEUTICS, INC. Files SEC form 8-K, Other Events, Financial Statements and Exhibits
08:00AM  CytomX Announces U.S. FDA Clearance of Investigational New Drug Application for Phase 1/2 Clinical Study of Anti-PD-L1 Probody Therapeutic, CX-072 GlobeNewswire
Dec-13-16 02:05PM  Is CytomX Therapeutics Inc (CTMX) A Good Stock To Buy? at Insider Monkey
08:03AM  CYTOMX THERAPEUTICS, INC. Files SEC form 8-K, Other Events, Financial Statements and Exhibits
08:00AM  CytomX Announces Selection by Bristol-Myers Squibb of First Clinical Candidate Probody From Collaboration GlobeNewswire
07:44AM  CytomX Therapeutics, Inc. breached its 50 day moving average in a Bearish Manner : CTMX-US : December 13, 2016
Dec-12-16 08:52AM  Is Kforce Inc. (KFRC) A Good Stock To Buy? at Insider Monkey
Dec-09-16 01:16PM  ETFs with exposure to CytomX Therapeutics, Inc. : December 9, 2016
Dec-05-16 08:03AM  CYTOMX THERAPEUTICS, INC. Files SEC form 8-K, Other Events, Financial Statements and Exhibits
08:00AM  CytomX Announces Fourth Target Selection by Bristol-Myers Squibb Under Strategic Oncology Collaboration GlobeNewswire
Nov-22-16 10:50AM  CytomX Therapeutics, Inc. :CTMX-US: Earnings Analysis: Q3, 2016 By the Numbers : November 22, 2016
Nov-09-16 04:05PM  CytomX to Present at the Jefferies 2016 London Healthcare Conference GlobeNewswire
Nov-03-16 07:36PM  CytomX Therapeutics reports 3Q loss
04:07PM  CYTOMX THERAPEUTICS, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and
04:05PM  CytomX Therapeutics Announces Third Quarter 2016 Financial Results and Provides Pipeline Update GlobeNewswire
07:07AM  Q3 2016 CytomX Therapeutics Inc Earnings Release - After Market Close
Oct-27-16 08:00AM  CytomX Therapeutics to Announce Third Quarter 2016 Financial Results GlobeNewswire
Oct-21-16 10:26AM  ETFs with exposure to CytomX Therapeutics, Inc. : October 21, 2016
Oct-13-16 08:22AM  CytomX Therapeutics, Inc. breached its 50 day moving average in a Bearish Manner : CTMX-US : October 13, 2016
Sep-23-16 10:07AM  ETFs with exposure to CytomX Therapeutics, Inc. : September 23, 2016 -6.12%
Sep-12-16 10:47AM  ETFs with exposure to CytomX Therapeutics, Inc. : September 12, 2016 +5.93%
Aug-23-16 11:40AM  ETFs with exposure to CytomX Therapeutics, Inc. : August 23, 2016 +6.10%
Aug-10-16 01:30PM  CytomX Therapeutics, Inc. :CTMX-US: Earnings Analysis: Q2, 2016 By the Numbers : August 10, 2016
Aug-03-16 05:21PM  CytomX Therapeutics reports 2Q loss
04:07PM  CYTOMX THERAPEUTICS, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and
04:01PM  CytomX Announces Second Quarter 2016 Financial Results GlobeNewswire
07:07AM  Q2 2016 CytomX Therapeutics Inc Earnings Release - After Market Close
Jul-27-16 04:30PM  CytomX Therapeutics to Announce Second Quarter 2016 Financial Results and Provide Mid-Year Update GlobeNewswire
08:15AM  CytomX Therapeutics, Inc. breached its 50 day moving average in a Bearish Manner : CTMX-US : July 27, 2016
Jul-18-16 03:38PM  CytomX Therapeutics, Inc. Value Analysis (NASDAQ:CTMX) : July 18, 2016
Jul-11-16 08:04AM  CytomX Therapeutics, Inc. breached its 50 day moving average in a Bullish Manner : CTMX-US : July 11, 2016
Jul-01-16 02:46PM  These 5 Stocks Are Ready for Breakouts
Jun-26-16 09:31AM  7 Stocks Under $10 to Trade for Big Post-Brexit Gains
Jun-13-16 04:06PM  CYTOMX THERAPEUTICS, INC. Files SEC form 8-K, Change in Directors or Principal Officers, Submission of Matters to a V
08:00AM  CytomX Therapeutics Appoints John A. Scarlett, M.D., to Board of Directors GlobeNewswire
Jun-01-16 12:30PM  CytomX Therapeutics, Inc. :CTMX-US: Earnings Analysis: Q1, 2016 By the Numbers : June 1, 2016
May-24-16 08:00AM  CytomX to Present at the Jefferies 2016 Healthcare Conference GlobeNewswire
May-06-16 07:10AM  CytomX Therapeutics reports 1Q loss
07:03AM  CYTOMX THERAPEUTICS, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and
07:03AM  CYTOMX THERAPEUTICS, INC. Files SEC form 10-Q, Quarterly Report
07:00AM  CytomX Announces First Quarter 2016 Financial Results GlobeNewswire
Apr-28-16 04:10PM  CYTOMX THERAPEUTICS, INC. Files SEC form 8-K, Change in Directors or Principal Officers
01:11PM  ETFs with exposure to CytomX Therapeutics, Inc. : April 28, 2016
Apr-27-16 08:27AM  CytomX Therapeutics, Inc. breached its 50 day moving average in a Bearish Manner : CTMX-US : April 27, 2016
Apr-26-16 08:00AM  CytomX to Present at the 2016 Bank of America Merrill Lynch Healthcare Conference GlobeNewswire -6.42%
Apr-21-16 05:00PM  CytomX AbbVie Probody Drug Conjugates Collaboration Call scheduled for 5:00 pm ET today CCBN
04:13PM  CYTOMX THERAPEUTICS, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Regulation FD Disclosure, F EDGAR Online
04:01PM  CytomX and AbbVie Announce Strategic Collaboration for Probody Drug Conjugates GlobeNewswire
04:01PM  AbbVie and CytomX Announce Strategic Collaboration for Probody Drug Conjugates PR Newswire
Apr-18-16 03:00PM  Drug giant plots Peninsula expansion, 150 more jobs at bizjournals.com
Apr-05-16 08:04AM  CytomX Therapeutics, Inc. breached its 50 day moving average in a Bullish Manner : CTMX-US : April 5, 2016
Mar-16-16 04:30PM  CytomX Announces Data to be Presented at the American Association for Cancer Research Annual Meeting 2016 GlobeNewswire
Mar-15-16 12:42PM  ETFs with exposure to CytomX Therapeutics, Inc. : March 15, 2016
Mar-14-16 10:12AM  CytomX Therapeutics, Inc. :CTMX-US: Earnings Analysis: Q4, 2015 By the Numbers
Mar-07-16 02:25PM  CYTOMX THERAPEUTICS, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Change in Directors or P
09:54AM  CytomX Therapeutics reports 4Q loss
09:20AM  CYTOMX THERAPEUTICS, INC. Files SEC form 10-K, Annual Report
08:05AM  CytomX Announces Year-End 2015 Financial Results GlobeNewswire
Mar-03-16 08:00AM  CytomX to Present at Cowen and Companys 36th Annual Health Care Conference GlobeNewswire
Feb-23-16 10:00AM  CytomX Therapeutics, Inc. (Nasdaq:CTMX) to Ring The Nasdaq Stock Market Closing Bell GlobeNewswire
Feb-22-16 01:04PM  CYTOMX THERAPEUTICS, INC. Files SEC form 8-K, Regulation FD Disclosure
Jan-20-16 08:01AM  CYTOMX THERAPEUTICS, INC. Files SEC form 8-K, Other Events, Financial Statements and Exhibits +17.68%
Preclinical biotech developing tumor-activated cancer immunotherapies.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
McCarthy Sean A.President and CEOMar 20Option Exercise0.9514,34313,55416,322Mar 21 06:04 PM
Goeltz II Robert C.Chief Financial OfficerMar 20Option Exercise4.4721,51796,24131,306Mar 21 06:05 PM
Goeltz II Robert C.Chief Financial OfficerMar 20Sale19.8121,517426,3409,789Mar 21 06:05 PM
McCarthy Sean A.President and CEOMar 20Sale19.6014,343281,1231,979Mar 21 06:04 PM
Goeltz II Robert C.Chief Financial OfficerMar 09Option Exercise4.472,50011,1829,789Mar 09 07:22 PM
McCarthy Sean A.President and CEOMar 03Option Exercise1.1314,34316,26416,322Mar 03 05:36 PM
McCarthy Sean A.President and CEOMar 03Sale15.0014,343215,1451,979Mar 03 05:36 PM
HUMPHREY RACHELChief Medical OfficerDec 28Option Exercise6.6115,11799,99415,117Dec 29 03:52 PM
SHANNON TIMOTHY MDirectorNov 29Sale11.1822,086247,0083,244,381Dec 01 02:35 PM
Canaan IX L.P.DirectorNov 29Sale11.1822,086247,0083,644,381Dec 01 02:27 PM
SHANNON TIMOTHY MDirectorNov 28Sale11.3320,840236,1423,666,467Nov 28 05:50 PM
Canaan IX L.P.DirectorNov 28Sale11.3320,840236,1423,666,467Nov 28 05:10 PM
SHANNON TIMOTHY MDirectorNov 25Sale11.796,72979,3413,687,307Nov 28 05:50 PM
Canaan IX L.P.DirectorNov 25Sale11.796,72979,3413,687,307Nov 28 05:10 PM
SHANNON TIMOTHY MDirectorNov 23Sale11.8410,890128,9213,694,036Nov 28 05:50 PM
Canaan IX L.P.DirectorNov 23Sale11.8410,890128,9213,694,036Nov 28 05:10 PM
SHANNON TIMOTHY MDirectorNov 22Sale11.7142,550498,0783,704,926Nov 22 07:01 PM
Canaan IX L.P.DirectorNov 22Sale11.7142,550498,0783,704,926Nov 22 06:48 PM
SHANNON TIMOTHY MDirectorNov 21Sale11.7213,548158,7853,747,476Nov 21 06:56 PM
Canaan IX L.P.DirectorNov 21Sale11.7213,548158,7853,747,476Nov 21 06:48 PM
SHANNON TIMOTHY MDirectorNov 18Sale11.6412,805149,0853,761,024Nov 21 06:56 PM
Canaan IX L.P.DirectorNov 18Sale11.6412,805149,0853,761,024Nov 21 06:48 PM
SHANNON TIMOTHY MDirectorNov 17Sale11.5018,971218,2183,773,829Nov 21 06:56 PM
Canaan IX L.P.DirectorNov 17Sale11.5018,971218,2183,773,829Nov 21 06:48 PM
SHANNON TIMOTHY MDirectorNov 16Sale11.5518,517213,9533,792,800Nov 16 07:33 PM
Canaan IX L.P.DirectorNov 16Sale11.5518,517213,9533,792,800Nov 16 07:13 PM
SHANNON TIMOTHY MDirectorNov 15Sale11.4833,064379,4763,811,317Nov 16 07:33 PM
Canaan IX L.P.DirectorNov 15Sale11.4833,064379,4763,811,317Nov 16 07:13 PM
SHANNON TIMOTHY MDirectorNov 14Sale11.2123,744266,0563,844,381Nov 14 05:41 PM
Canaan IX L.P.DirectorNov 14Sale11.2123,744266,0563,844,381Nov 14 04:41 PM
SHANNON TIMOTHY MDirectorNov 11Sale11.2035,391396,4613,868,125Nov 14 05:41 PM
Canaan IX L.P.DirectorNov 11Sale11.2035,391396,4613,868,125Nov 14 04:41 PM
SHANNON TIMOTHY MDirectorNov 10Sale11.0727,135300,3903,903,516Nov 14 05:41 PM
Canaan IX L.P.DirectorNov 10Sale11.0727,135300,3903,903,516Nov 14 04:41 PM
SHANNON TIMOTHY MDirectorNov 09Sale11.0313,730151,4983,930,651Nov 10 04:41 PM
Canaan IX L.P.DirectorNov 09Sale11.0313,730151,4983,930,651Nov 10 04:36 PM
Goeltz II Robert C.Chief Financial OfficerSep 29Option Exercise4.474,00017,8916,000Oct 03 02:32 PM